Peregrine Pharmaceuticals (PPHM) dips 6.5% in post-session trading after filing a $75M...


Peregrine Pharmaceuticals (PPHM) dips 6.5% in post-session trading after filing a $75M at-the-market secondary sales agreement with MLV & Company.
From other sites
Comments (2)
  • PPHMstockofcentury
    , contributor
    Comments (26) | Send Message
     
    Peregrine getting ready for a major Partnering deal? Its the only reasonable explanation. No other reason they needed to do this at this time and leverage with partner(s) ? Time will tell
    29 Dec 2012, 07:10 AM Reply Like
  • Jimo14
    , contributor
    Comment (1) | Send Message
     
    This could be bad news or good news.
    30 Dec 2012, 05:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs